98%
921
2 minutes
20
Background And Purpose: Robotic devices that provide passive guidance and stabilization of the legs and trunk during treadmill stepping may increase the delivery of locomotor training to subjects with neurological injury. Lower-extremity guidance also may reduce voluntary muscle activity as compared with compliant assistance provided by therapists. The purpose of this study was to investigate differences in metabolic costs and lower-limb muscle activity patterns during robotic- and therapist-assisted treadmill walking.
Subjects: Twelve ambulatory subjects with motor incomplete spinal cord injury participated.
Methods: In 2 separate protocols, metabolic and electromyographic (EMG) data were collected during standing and stepping on a treadmill with therapist and robotic assistance. During robotic-assisted walking, subjects were asked to match the kinematic trajectories of the device and maximize their effort. During therapist-assisted walking, subjects walked on the treadmill with manual assistance provided as necessary.
Results: Metabolic costs and swing-phase hip flexor EMG activity were significantly lower when subjects were asked to match the robotic device trajectories than with therapist-assisted walking. These differences were reduced when subjects were asked to maximize their effort during robotic-assisted stepping, although swing-phase plantar-flexor EMG activity was increased. In addition, during standing prior to therapist- or robotic-assisted stepping, metabolic costs were higher without stabilization from the robotic device.
Discussion And Conclusion: Differences in metabolic costs and muscle activity patterns between therapist- and robotic-assisted standing and stepping illustrate the importance of minimizing passive guidance and stabilization provided during step training protocols.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2522/ptj.20050266 | DOI Listing |
J Intensive Care Med
September 2025
Independent Researcher, Outcomes Research, Atlanta, GA, USA.
Purpose: Obesity is a risk factor for sepsis complications in older adults. We assessed the impact of metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO) on outcomes in septic shock.
Methods: We conducted a retrospective analysis using the National Inpatient Sample (2016-2020) to identify a cohort of 1,737,075 patients aged 65 years and older who were hospitalized with septic shock, as defined by ICD-10 diagnosis codes.
Liver Int
October 2025
The Global NASH Council, Washington, DC, USA.
Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.
Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.
Adv Sci (Weinh)
September 2025
Faculty of Engineering, University of Technology Sydney, P.O. Box 123, Broadway, Sydney, NSW, 2007, Australia.
Microalgae-bacteria symbiosis system is significant for sustainable and low-carbon wastewater treatment, with self-aggregation being key to its stable operation and effective pollutant removal. Cellular motility is the main driving force behind self-aggregation, crucial for symbiosis stability, but the characteristics and patterns involved still remain largely unexplored. Here, cellular movement dynamics into the microalgae-activated sludge model (ASM3) is incorporated, enabling synchronized simulation of metabolic activities and movement behaviors through physical and biochemical interactions in bioreactor systems.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
August 2025
Animal Genetics, University of Tuebingen, 72076 Tuebingen, Germany.
Background: Membrane transport proteins are critical determinants of systemic and intracellular drug levels, thereby contributing substantially to drug response and/or adverse drug reactions. Therefore, the U.S.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
August 2025
Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, 9010 Dunedin, New Zealand.
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function, significantly contributing to frailty, disability, and mortality in aging populations. As life expectancy rises, sarcopenia presents a growing public health challenge, increasing healthcare costs, and diminishing quality of life. Despite its prevalence, sarcopenia is often underdiagnosed due to limitations in current diagnostic tools, including the lack of standardized cut-off values and reliance on physical performance tests.
View Article and Find Full Text PDF